160
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Effects and safety profile of betahistine in patients in the Russian contingent of OSVaLD, an open-label observational study in vestibular vertigo

, , , &
Pages 47-53 | Published online: 22 Jan 2015

References

  • BeneckeHPérez-GarriguesHBin SidekDOSVaLD InvestigatorsEffects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD studyInt Tinnitus J201016142421609908
  • Pérez-GarriguesHKuessnerDBeneckeHPatient baseline characteristics in a multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD studyCurr Med Res Opin2007232753276117910803
  • JacobsonGPNewmanCWThe development of the Dizziness Handicap InventoryArch Otolaryngol Head Neck Surg19901164244272317323
  • EnloeLJShieldsRKEvaluation of health-related quality of life in individuals with vestibular disease using disease-specific and general outcomes measuresPhys Ther1997778909039291947
  • JarlsäterSMattsonETest of reliability of the dizziness handicap inventory and the activities-specific balance confidence scale for use in SwedenAdv Physiother20035137144
  • KammerlindASLedinTESkargrenEIOdkvistLMReliability of clinical balance tests and subjective ratings in dizziness and disequilibriumAdv Physiother2005796107
  • WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selectionMed Care1992304734831593914
  • McHorneyCAWareJEJrRaczekAEThe MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructsMed Care1993312472638450681
  • McHorneyCAWareJEJrLuJFSherbourneCDThe MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groupsMed Care19943240668277801
  • Saris-BaglamaRNDeweyCJChisholmGBSF Health Outcomes™ Scoring Software User’s GuideLincoln, RI, USAQualityMetric Inc2004
  • SF-36v2™Scoring SF-36 ScalesLincoln, RI, USAQualityMetric Inc2000
  • ZigmondASSnaithRPThe Hospital Anxiety and Depression ScaleActa Psychiatr Scand1983673613706880820
  • BeneckeHAgusSKuessnerDGoodallGStruppMThe burden and impact of vertigo: findings from the REVERT Patient RegistryFront Neurol2013413624106487
  • WhitneySLHudakMTMarchettiGFThe activities-specific balance confidence scale and the dizziness handicap inventory: a comparisonJ Vestib Res1999925325910472037
  • TamberALWilhelmsenKTStrandLIMeasurement properties of the Dizziness Handicap Inventory by cross-sectional and longitudinal designsHealth Qual Life Outcomes2009710120025754
  • NautaJJMeta-analysis of clinical studies with betahistine in Ménière’s disease and vestibular vertigoEur Arch Otorhinolaryngol201427188789723778722
  • KostenkoEVPetrovaLVTorgovanovaEATreatment of vestibular vertigo and Ménière syndrome in outpatient clinicsZh Nevrol Psikhiatr Im S S Korsakova20121123640 Russian23388590
  • GornostaevaGVIuIaVarakinProkopovichMEAlekseevaNSFedinPAChechetkinAOEpidemiology, clinical features and Betaserc therapy of vertigo in initial and reversible cerebrovascular pathologyZh Nevrol Psikhiatr Im S S Korsakova20051051417 Russian16250576
  • LarikovaTICherevikovaGMBetaserc and improvement of life quality in war veteransZh Nevrol Psikhiatr Im S S Korsakova20051056870 Russian15822746
  • GekhtABVialkovaABGalanovDVClinico-neurological and stabilometric analysis of betahistine (Betaserc) efficacy in patients with vertigo in the rehabilitation period of ischemic strokeZh Nevrol Psikhiatr Im S S Korsakova2005Suppl 153238 Russian16447551
  • StambolievaKAngovGEffect of treatment with betahistine dihydrochloride on the postural stability in patients with different duration of benign paroxysmal positional vertigoInt Tinnitus J201016323621609911
  • StruppMKremmydaOBrandtTPharmacotherapy of vestibular disorders and nystagmusSemin Neurol20133328629624057832
  • LeziusFAdrionCMansmannUJahnKStruppMHigh-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Ménière’s disease: a case seriesEur Arch Otorhinolaryngol20112681237124021626121
  • StruppMHupertDFrenzelCLong-term prophylactic treatment of attacks of vertigo in Ménière’s disease – comparison of a high with a low dosage of betahistine in an open trialActa Otolaryngol200812852052418421605
  • StruppMBrandtTDiagnosis and treatment of vertigo and dizzinessDtsch Arztebl Int200810517318019629221
  • CavalieriMMottolaGIemmaMBenign paroxysmal positional vertigo: a study of two manoeuvres with and without betahistineActa Otorhinolaryngol Ital20052510711216116833
  • HornibrookJBenign paroxysmal positional vertigo (BPPV): history, pathophysiology, office treatment and future directionsInt J Otolaryngol2011201183567121808648
  • GauthierSJubyAMorelliLRehelBSchecterRA large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND StudyCurr Med Res Opin2006222251226517076986
  • von ElmEAltmanDGEggerMPocockSJGøtzschePCVandenbrouckeJPThe Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesPLoS One20074e296
  • Jeck-TholeSWagnerWBetahistine: a retrospective synopsis of safety dataDrug Saf2006291049105917061910